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RHEUMATOLOGY

Original article
A double-blind, placebo-controlled, phase II,
randomized study of lovastatin therapy in the
treatment of mildly active rheumatoid arthritis
Cynthia Aranow1, John Cush2, Marcy B. Bolster3, Christopher C. Striebich4,
Maria Dall’era5, Meggan Mackay1, Ewa Olech6, Tracy Frech7, Jane Box8,
Richard Keating9, Mary Chester Wasko10, William St Clair11, Alan Kivitz12,
Weiquang Huang1, PetaGay Ricketts1, Beverly Welch13, Sherrie Callahan13,
Meagan Spychala14, Karen Boyle14, Kate York14, Lynette Keyes-Elstein14,
Ellen Goldmuntz13, Betty Diamond1 and Anne Davidson1
Abstract
for hyperlipidaemia. In addition to lipid-lowering abilities, statins exhibit multiple anti-inflammatory effects. The objectives
of this study were to determine whether treatment of patients with RA with lovastatin decreased CRP or reduced disease
activity.
Methods. We conducted a randomized double-blind placebo-controlled 12 week trial of lovastatin vs placebo in 64 RA
patients with mild clinical disease activity but an elevated CRP. The primary efficacy end point was the reduction in mean
log CRP. Secondary end points included disease activity, RF and antiCCP antibody titres. Mechanistic end points
included levels of serum cytokines. Safety was assessed; hepatic and muscle toxicities were of particular interest.
Results. Baseline features were similar between groups. No significant difference in mean log CRP reduction between
the two groups was observed, and disease activity did not change from baseline in either treatment group. Mechanistic
analyses did not reveal significant changes in any biomarkers. A post hoc analysis of subjects not using biologic therapy
demonstrated a significantly greater proportion achieving 520% reduction in CRP from baseline in the lovastatin group
compared with placebo (P-value = 0.007). No difference was observed in subjects receiving biologics. Lovastatin was
well tolerated with no serious safety concerns.
Conclusion. This study showed no anti-inflammatory or clinical effects on RA disease activity after 12 weeks of treatment with lovastatin. Lovastatin had a modest effect on CRP in subjects not using biologics, suggesting statins may be
anti-inflammatory in selected patients.
Trial registration. ClinicalTrials.gov, http://clinicaltrials.gov, NCT00302952.
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Rheumatology key messages
Statins (HMG Co-Reductase Inhibitors) have multiple properties beyond cholesterol reduction, which include antiinflammatory actions.
. 12 weeks of lovastatin in patients with mildly active RA had no adjunctive therapeutic effects.
. RA patients who were not receiving biologic therapies achieved 520% reduction in CRP with lovastatin.
.
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CLINICAL
SCIENCE

Objectives. 3-hydroxy-3-methylglutaryl coenzyme-A (HMG Co-A) reductase inhibitors (statins) are standard treatment

Cynthia Aranow et al.

Introduction
3-hydroxy-3-methylglutaryl coenzyme-A (HMG Co-A) reductase inhibitors (statins) lower lipid levels, reduce cardiovascular events and mortality, and have numerous
anti-inflammatory and immunomodulatory properties.
Statins decrease production of inflammatory chemokines
and cytokines by T cells and macrophages, decrease the
viability of plasma cells [14], and inhibit endothelial cell
activation and angiogenesis [57]. In individuals with
normal lipid profiles, statins reduce inflammatory markers
and improve cardiovascular outcomes [8, 9]. These
anti-inflammatory effects are attributed to reductions in
mevalonate, a cholesterol precursor. Mevalonate is also
a precursor for isoprenoid intermediates required for the
functioning of guanosine triphosphatases (GTPases), Ras,
Rho and Rab, which control cell behaviour through signal
transduction pathways. In addition, statins, particularly
lovastatin, may sterically inhibit the interaction of lymphocyte function-associated antigen (LFA-1) with its ligand
intracellular adhesion molecule (ICAM-1) in a mevalonate-independent manner [10].
Given these properties, we conducted a prospective
trial evaluating the anti-inflammatory effect and efficacy
of lovastatin, a statin with potent in vivo and in vitro antiinflammatory properties, as a non-toxic adjunct therapy in
RA patients with mild clinical disease activity. This study
examined the short-term effects of exposure to lovastatin
on serum CRP, disease activity and a number of RArelated biologic markers.

Methods
In this multicentre, double-blind, Phase II trial
(ClinicalTrials.gov Identifier NCT00302952), subjects with
RA, with mild clinical disease activity, were randomized
(1:1) to receive placebo or 80 mg lovastatin daily for
12 weeks. A dose of 80 mg/day of lovastatin was based
upon drug concentrations used in in vitro studies. The
primary objective was to examine the effect of lovastatin
on CRP. Secondary objectives included evaluating the effects of lovastatin on disease activity, as well as assessing
safety and tolerability. Disease activity was measured
using DAS28-CRP, and clinical response was determined
by ACR20 response and DAS28-CRP EULAR (European
League Against Rheumatism) response indices [11, 12])].
Mechanistic objectives included exploring effects of
lovastatin on RF and anti-CCP autoantibody titres, inflammatory mediators and pathways, and autoreactive B cells.
Subjects meeting 1987 ACR classification criteria for RA
with mildly active clinical disease, defined by joint counts
(28 tender joints and 16 swollen joints) and an elevated
CRP (>5 mg/l) were recruited. DMARD and/or biologic
therapy and/or stable prednisone 410 mg/day were
permitted; however, the addition or increase of medications for RA disease activity during the study was prohibited. Exclusion criteria included statin use, infection,
myositis, treatment with medications metabolized using
the cytochrome P3A4 pathway, elevated creatinine phosphokinase, serum alanine aminotransaminase, aspartate
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aminotransaminase, or serum creatinine, pregnancy or
ACR Functional Status Class IV. Treatment with infliximab
within 3 months of screening or prior treatment with rituximab were also exclusions due to concerns about a loss of
drug effect and a subsequent rebound of disease activity
occurring during a subject’s participation in the clinical trial.
Institutional Review Boards approved the study at each site
and the NIAID Autoimmune Data and Safety Monitoring
Board provided study oversight. All participants provided
informed consent prior to initiation of study procedures.
Eligible subjects were randomized using an adaptive
randomization scheme to ensure balance on key baseline
characteristics [13]: DAS28-CRP, race, MTX use, anti-TNF
use, and disease duration.
Per protocol, temporary discontinuation of study treatment or dose adjustments were allowed for elevations in
transaminase or creatinine phosphokinase levels, study
drug intolerance, development of a condition that
increased the risk for statin-related myopathy, or an
adverse event (AE). Upon resolution, the study drug
could be resumed and continued at 40 mg/day.

Laboratory assessments
Local laboratories performed screening CRP assessments. Sera for subsequent CRP measurements were
batched and assessed centrally. At baseline and end-ofstudy, lipid levels, RF, anti-CCP antibodies, and a panel of
18 potential RA biomarkers were evaluated centrally. RF
was measured by an ELISA using human IgG fragment
crystallizable (IgG Fc) (Southern Biotech, Birmingham,
AL) [14]. Anti-CCP was measured using the QUANTA
Lite CCP3 IgG assay (QUANTA Lite, Inova Diagnostics
Inc, Davis CA). Analytes on the biomarker panel (MIP1a,
G-CSF, IFNg, IL1b, ICAM-1, IL6, OPG, VCAM-1, IL12p70,
IL10, IL17A, RANTES, TNF, RANKL, MCP-1, IL1RA, Eselectin, and BAFF) were measured using a magnetic
bead multiplexed assay (Affymetrix, San Diego CA).
IgM-secreting B cells were enumerated in Dr
Davidson’s laboratory at the Feinstein Institute by
ELISpot (Enzyme-Linked ImmunoSpot) on a subset of 9
subjects (6 placebo, 3 lovastatin) enrolled at the Feinstein
Institute, using fresh peripheral blood mononuclear cells
(PBMCs) [15]. Statins inhibit the release of monocyte
chemoattractant protein-1 (MCP-1) from PBMCs following
mitogen stimulation in a mevalonate-dependent manner
[16]. We conducted additional mechanistic studies to
evaluate this anticipated effect. PBMCs obtained from
the same subset of 9 subjects on days 0 and 84 were
treated with lipopolysaccharide (LPS) 100 ng/ml (Sigma
Aldrich, St Louis, MO) in the presence of lovastatin10 uM
(Teva Pharmaceuticals, Parsippany, NJ), mevalonate
100 mM (Sigma Aldrich, St Louis, MO) or lovastatin +
mevalonate. Control wells received no stimulation.
Supernatants were harvested after 24 hours and tested
for MCP-1 by ELISA (eBioscience, San Diego CA).

Sample size and statistical analyses
The primary efficacy outcome was the change in mean log
CRP from baseline to day 84. A 50% reduction in CRP
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was observed in a study of atorvastatin in RA (TARA). In
TARA, the mean (standard deviation) of log CRP was 2.5
(1.2) log mg/l at baseline [17]. After 6 months of treatment,
the difference in mean change in log CRP between groups
was 0.58. Assuming a consistent standard deviation
over time (1.2 log mg/l) and a correlation of 0.75 between
baseline and follow-up, 34 subjects per arm gives 80%
power to detect the identical group difference using a 2sided test with a = 0.05. The planned enrolment was 40
per arm to account for potential dropouts.
Pre-specified secondary end points included DAS28CRP, DAS28-CRP EULAR response, ACR20 response,
RF, anti-CCP antibody titres, and serum concentrations
of biomarkers. In addition, achievement of a 15% reduction of CRP was pre-specified for this trial, as a reduction
of this magnitude was previously observed in a trial of
lovastatin for primary prevention of coronary events [9].
A 20% reduction of CRP was added post hoc given its
role in contributing to the achievement of an ACR20 response [11].
A modified intent-to-treat (mITT) population was defined
as randomized participants receiving at least one dose of
study drug and possessing a baseline CRP. The primary
efficacy analysis included mITT subjects whose visit at
day 84 (14 days) was within 7 days of their last dosing
day. Secondary analyses included mITT subjects with
available data. Analysis of adverse events used the
safety population, consisting of all participants receiving
at least 1 dose of study drug.
For the primary end point, an analysis of covariance
model was used to compare treatment groups after adjusting for baseline log CRP, baseline DAS28-CRP, race,
MTX use, anti-TNF use, and disease duration. Summary
statistics for CRP are presented on the untransformed
scale. Continuous secondary efficacy end points were
analysed in a similar fashion except that only covariates
significant at the 0.05 level were included in the final
models. Categorical end points were evaluated using
Pearson’s 2 test or a Fisher’s exact test. Changes in
lipid profiles from baseline were evaluated using t-tests.
Post hoc analyses included comparisons between treatment arms in subjects using and not using biologic
agents.
The primary hypothesis was evaluated at the 0.05 level
of significance. Secondary analyses were considered exploratory; P-values are presented without adjustment for
multiple comparisons.

Results
A total of 132 subjects were screened at 15 centres, and
64 were randomized (Fig. 1). The study was prematurely
terminated because of slow enrolment and study drug
expiration; patients meeting the definition of mildly
active clinical disease and sufficiently elevated CRP
proved difficult to identify. The safety population included
all 64 randomized subjects (34 lovastatin, 30 placebo).
The mITT population comprised 63 participants (34 lovastatin, 29 placebo); 55 (30 lovastatin, 25 placebo) of which
met requirements for inclusion in the primary analysis.
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Thirty (88.2%) lovastatin and 24 (82.8%) placebo subjects
received 580% of expected doses.

Baseline characteristics
Baseline characteristics of subjects were consistent with
expectations for a RA population with mild clinical activity
(Table 1). Study participants had mildly active clinical disease with a mean of 4.6 tender joints and 3.6 swollen
joints. The mean (S.D.) baseline CRP levels were 12.2
(11.42) and 12.6 (16.43) mg/l for lovastatin and placebo
groups, respectively. DAS-28 scores were similar in the
lovastatin and placebo groups (3.9 and 4.2 respectively).
As DAS-28 incorporates measurement of an acute phase
reactant (i.e. CRP), which was required to be elevated for
study entry, patients in this study had mild to moderate
DAS-defined RA disease activity. The treatment groups
were similar except for biologic use, which was numerically higher in the lovastatin arm (58.8%) than in the placebo arm (37.9%).

Overall efficacy
CRP levels did not change appreciably from baseline to
day 84 [mean (S.E.) for change in CRP (mg/l): 2.0 (1.2)
lovastatin; 2.2 (1.0) placebo (Table 2)]. Treatment groups
did not differ significantly after adjustment for baseline
CRP and pre-specified covariates (P-value = 0.8, primary
analysis). Subjects with higher baseline disease activity
DAS or log CRP did tend to have a greater decline in
log CRP over the 84 days of study after accounting for
other factors (P-value = 0.017, P-value = 0.272,
ANCOVA). Since infection can raise CRP values, an analysis was performed excluding the 6 subjects, 3 lovastatin
and 3 placebo treated, with an infection at day 84; the
differences between treatment groups remained non-significant. Additional sensitivity analyses such as excluding
outliers and imputing missing data, did not change the
result of this analysis.
A 515% reduction in day 84 CRP was achieved by
61.3% and 44.0% of subjects in the lovastatin and placebo groups, respectively (P-value = 0.3, Fisher’s exact
test; Table 3). In addition, a reduction of 520% was
observed in 54.8% and 32.0% in the lovastatin and placebo groups, respectively (P-value = 0.1, Fisher’s exact
test).
Lovastatin had no significant effect on disease activity.
The mean change (S.E.) in DAS28-CRP from baseline to
day 84 was 0.4 (0.2) and 0.6 (0.2) in the lovastatin and
placebo arms, respectively (P-value = 0.5). Furthermore,
lovastatin did not significantly affect either DAS-28 CRP
EULAR or ACR20 responder indices at day 84. For the
DAS28-CRP EULAR index, 45% and 48% of lovastatin
and placebo subjects, respectively, met the response criteria (P-value = 0.8). For ACR20, 29% and 40% of lovastatin and placebo subjects, respectively, met response
criteria (P-value = 0.4).
There were no significant changes in autoantibody
titres, RF or anti-CCP antibody from baseline to day 84
in either arm, and there were no differences between arms
(see Supplementary Figure S1, available at Rheumatology
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FIG. 1 Flow chart showing disposition of the study subjects

AE: adverse event; AST: serum aspartate transaminase; ULN: upper limit of normal.

online). In the limited sample of 9 subjects (6 placebo, 3
lovastatin), RF-secreting B cells were detected in all
subjects.

Evaluation of efficacy with and without biologic use
Exploratory analyses compared the effects of lovastatin
on subjects who did and did not use biologic agents
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(Table 2). Among those who did not use biologics, CRP
levels at baseline were comparable between groups
[mean (S.E.) mg/l: 16.6 (4.7) lovastatin, 16.2 (5.8) placebo].
Changes in CRP from baseline to day 84 did not differ
significantly between lovastatin- and placebo-treated
groups [mean (S.E.) mg/l: 4.8 (3.0) lovastatin; 2.0 (1.7)
placebo; P-value = 0.1 Wilcoxon]. In subjects receiving
biologics, baseline CRP levels were lower than in those
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TABLE 1 Demographic and baseline characteristics by
treatment group (mITT)

Parameter
Agea
Female (%)
Hispanic (%)
Race, White (%)
Black (%)
Other (%)
Disease duration (years)a
Current biologic use (%)
CRP (mg/l)a
Tender joint counta
Swollen joint counta
Patient Global Disease
Activitya
DAS28a
ACR functional class, I (%)
II (%)
III (%)
Cholesterola
LDL-cholesterola
HDL-cholesterola
Triglyceridea

Lovastatin
(N = 34)

Placebo
(N = 29)

55.8
32
6
26
6
2
12.5
20
12.2
4.4
3.5
3.5

(7.1)
(94.1)
(17.6)
(76.5)
(17.6)
(5.9)
(9.6)
(58.8)
(11.4)
(2.5)
(1.4)
(2.3)

52.6
28
8
20
5
4
11.9
11
12.6
4.8
3.8
4.5

(10.4)
(96.6)
(27.6)
(69.0)
(17.2)
(13.8)
(12.6)
(37.9)
(16.4)
(2.2)
(1.6)
(1.6)

3.9(0.7)
20 (58.8)
12 (35.3)
2 (5.9)
190 (39.2)
117 (31.0)
48 (14.4)
125 (73.1)

4.2
15
9
5
196
120
51.4
124.7

(0.4)
(51.7)
(31.0)
(17.2)
(31.0)
(26.9)
(14.3)
(60.0)

a

Mean (S.D.). Note: The biologic agents used by patients in
this trial were: abatacept, adalimumab, betaseron, certolizumab pegol, etanercept, and ustekinumab. Betaseron was
used in a patient with concomitant multiple sclerosis, and
ustekinumab was used in a patient with psoriasis with no
evidence of PsA. LDL: low-density lipoprotein; HDL: highdensity lipoprotein; mITT: modified intent-to-treat.

not receiving biologics, but were comparable between
arms [mean (S.E.) mg/l: 7.9 (1.1) lovastatin; 7.9 (0.9) placebo]. Changes in CRP from baseline to day 84 were
smaller for lovastatin compared with placebo but the difference was not statistically significant [mean (S.E.) mg/l:
1.2 (1.0) lovastatin;
2.4 (0.9) mg/l placebo; Pvalue = 0.2 Wilcoxon]. Furthermore, irrespective of biologic use, clinical response criteria (DAS28-CRP EULAR
or ACR20) did not differ significantly between arms
(Table 3).
However, in subjects not using biologic agents, a significant difference was observed in the proportion of subjects reaching a meaningful reduction in CRP (520%) at
day 84 compared with baseline in the lovastatin arm (75%)
compared with the placebo arm (20%; P-value = 0.007,
Fisher’s exact). This difference was not evident in those
who used biologics (Table 3). Similar statistically significant results were observed in the 15% reduction in baseline CRP.

Mechanistic analyses
Serum levels of 18 inflammatory markers did not differ
between arms on Days 0 or 84, either overall or for subsets based on biologic use. Similar results were seen
when comparing individuals who received biologic
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agents with those who did not. Changes in cytokine
levels were uncorrelated with baseline DAS or CRP (see
Supplementary Figure S2, available at Rheumatology
online).
Statins can block MCP-1 secretion by LPS-stimulated
PBMCs in a mevalonate-dependent manner [16]. Among
9 participants, unstimulated PBMCs from day 0 produced
variable MCP-1 levels after 24 h of culture, and induction
by LPS occurred in only 5 individuals. The effect of exogenous lovastatin on suppression of MCP-1 was also
variable; no differences were detected either between
days 0 and 84 or between treatment groups (see
Supplementary Figure S3, available at Rheumatology
online).

Lipid profile
Significant improvements were seen in total cholesterol,
low-density lipoprotein and high-density lipoprotein in the
lovastatin arm compared with the placebo arm at day 84
[mean (S.E.) change (mg/dl): total 39 (5.3) lovastatin, 6
(3.9) placebo, P-value <0.001; low-density lipoprotein
39 (4.5) lovastatin, 6 (3.5) placebo, P-value < 0.001;
high-density lipoprotein 3.9 (1.5) lovastatin, 0.8 (1.6) placebo, P-value 0.04]. The change in triglycerides from
baseline to day 84 did not differ between arms [mean
(S.E.) change (mg/dl): 21.2 (11.8) lovastatin, 0.7 (9.2) placebo, P-value = 0.2].

Safety
The administration of a high-dose statin was well tolerated
without significant safety signals. Fifty-nine participants in
the safety population [29 (85%) lovastatin, 30 (100%) placebo] experienced 219 adverse events (AEs, 109 lovastatin, 110 placebo). Most AEs were mild (grade 1) including
abnormalities of laboratory values. There were no grade 4
or 5 events. Four subjects (2 lovastatin, 2 placebo) experienced six grade 3 events (2 lovastatin, 4 placebo). Two
serious AEs were reported: a subject (lovastatin) was hospitalized for an upper respiratory tract infection that was
deemed unrelated to the study therapy; a subject (placebo) was hospitalized for grade 3 haematemesis.
Seven subjects (4 lovastatin, 3 placebo) experienced transient elevations in creatinine phosphokinase. Eleven subjects (6 lovastatin, 5 placebo) experienced transaminase
abnormalities. Eight subjects (3 lovastatin, 5 placebo) prematurely discontinued study therapy and withdrew from
the study (Fig. 1), while 4 subjects (1 lovastatin, 3 placebo)
remained in the study but underwent a reduction of their
dose of the study drug or had a temporary discontinuation
but then resumed at 40 mg/day, per protocol. There were
no cases of myositis. Among the 36 musculoskeletal AEs,
6 subjects (4 lovastatin, 2 placebo) experienced new or
worsening arthralgia, and 2 subjects (1 per arm) experienced myalgia.

Discussion
Because of its numerous anti-inflammatory properties, we
evaluated lovastatin as a potential candidate for a safe

1509

Cynthia Aranow et al.

TABLE 2 CRP (mg/l) by treatment group and biologic use (mITT with available data)
Lovastatin
Primary analysisa
Day 0
Day 84
Change
No biologic useb
Day 0
Day 84
Change
Biologic useb
Day 0
Day 84
Change

Mean (S.E.)
Mean (S.E.)
Mean (S.E.)
Median (range)

10.8
8.8
2.0
1.1

Mean (S.E.)
Mean (S.E.)
Mean (S.E.)
Median range)

16.6
11.8
4.8
3.4

Mean (S.E.)
Mean (S.E.)
Mean (S.E.)
Median (range)

7.9
6.7
1.2
0.5

N = 30
(2.1)
(1.6)
(1.2)
( 22.1, 18.0)
N = 12
(4.7)
(3.5)
(3.0)
( 22.1, 18.0)
N = 19
(1.1)
(1.0)
(1.0)
( 15.1, 3.7)

Placebo
N = 25
(3.5)
(3.0)
(1.0)
( 18.0, 3.6)
N = 15
16.2 (5.8)
14.2 (4.7)
2.0 (1.7)
1.3 ( 18.0, 3.6)
N = 10
7.9 (0.9)
5.5 (0.9)
2.4 (0.9)
2.0 ( 6.7, 2.5)
12.9
10.7
2.2
0.6

P-value

0.8*

0.1**

0.1**

Note: Summary statistics for CRP are presented on the untransformed scale; P-values are based on the log CRP change from
baseline. aOnly subjects with the day 84 visit within 14 days of the day 84 target date and within 7 days of their last dosing day
were included in the primary efficacy analysis. bSecondary analyses were based on the mITT population; subjects with the day
84 visit >14 days from the day 84 target date were included. *P-value tested for treatment effect for the change from baseline
in log CRP using an analysis of covariance with adjustments for baseline log CRP, baseline DAS28-CRP score, race, MTX use,
anti-TNF use, and disease duration. **P-value for treatment effect for the change from baseline in log CRP in biologic users vs
non-users using a Wilcoxon rank sum test. mITT: modified intent-to-treat.

TABLE 3 Response rates by treatment group and biologic use (mITT with available data)

5 20% Reduction in CRP at day 84
No biologic use
Biologic use
Overall
515% Reduction in CRP at day 84
No biologic use
Biologic use
Overall
ACR20 Response at day 84
No biologic use
Biologic use
Overall
DAS28-CRP EULAR response at day 84
No biologic use
Biologic use
Overall

Lovastatin

Placebo

P-value

9/12 (75.0)
8/19 (42.1)
17/31 (54.8)

3/15 (20.0)
5/10 (50.0)
8/25 (32.0)

0.007*
0.71*
0.11*

10/12 (83.3)
9/19 (47.4)
19/31 (61.3)

5/15 (33.3)
6/10 (60.0)
11/25 (44.0)

0.019*
0.70*
0.28*

4/12 (33.3)
5/19 (26.3)
9/31 (29.0)

6/15 (40.0)
4/10 (40.0)
10/25 (40.0)

0.72**
0.45**
0.39**

5/12 (41.7)
9/19 (47.4)
14/31 (45.2)

7/15 (46.7)
5/10 (50.0)
12/25 (48.0)

0.80**
0.89**
0.83**

*P-values are from a Fisher’s exact test. **P-values are from a 2 test. mITT: modified intent-to-treat.

adjunct to existing RA therapies. The anti-inflammatory
effect of lovastatin on CRP, a marker of inflammation
was anticipated to occur relatively quickly after statin exposure. However, a 12 week course of lovastatin in RA
patients with mild clinical disease activity did not significantly reduce CRP levels compared with placebo. Neither
mean changes in CRP nor proportions achieving meaningful reductions of CRP (15 or 20%) differed significantly
between treatment arms. Although disease activity
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(DAS28-CRP) did not decline, a considerable proportion
of both lovastatin- and placebo-treated subjects met
DAS28-CRP EULAR or ACR20 response criteria. In the
placebo group, response rates were higher than expected
(ACR20: 40%, DAS28-CRP EULAR response: 48%), and
no difference was observed between treated and placebo
groups. The placebo response may be attributable to the
short study duration, and it may not have been sustained
in a longer study. Additionally, this study targeted subjects
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without severe disease activity, who may have been more
susceptible to the placebo response.
In addition to assessing the effect of lovastatin on disease activity and CRP, we studied a number of mechanistic end points, including autoantibody titres and a panel
of 18 potential protein biomarkers. Serum titres of autoantibodies and biomarkers correlate with changes in disease activity and may predict subsequent clinical
response [18]. Serum biomarkers may also respond to
successful therapeutic intervention, reflecting effects of
therapy on pathophysiologic pathways. In this study, IL6 and VCAM-1, robust markers of change in disease activity, remained stable in both lovastatin and placebo
groups. Additionally, although statins have known effects
on MCP-1, in vivo, these levels did not change after lovastatin exposure. However, since these studies were performed in a limited number of subjects, results are
inconclusive. Overall, the mechanistic findings are consistent with our observation that lovastatin had no effect
on either disease activity or on CRP.
Initial studies of statins in RA demonstrated a beneficial
effect on RA disease activity and CRP. In 2004, the TARA
study reported a significant improvement in DAS 28 and
CRP after 6 months of treatment with atorvastatin vs placebo [17]. These subjects entered the study with quite
active disease. Many, but not all, subsequent studies of
statins in RA have also demonstrated significant improvement in disease activity. Differences in trial duration, disease activity at enrolment, the statin studied and
background concomitant RA medications likely contributed to the response heterogeneity observed among these
studies [1929]. Our 12 week trial studied subjects with
mild clinical disease activity with a mean entry DAS28 of
4.0. In addition, our study population included subjects
using biologic agents, whereas in the TARA trial, no subjects received biologic therapy. These differences may
account for the differences observed between the two
trials.
Background medication may modulate the effect of statins on CRP. Although randomization of subjects was stratified by use of TNF inhibition (the predominant class of
biologic at the time this study was conducted), a greater
number of subjects randomized to lovastatin were receiving biologic agents than subjects receiving placebo.
Previous studies of statins in RA of subjects receiving
only DMARD therapy, without inclusion of subjects on
concomitant biologic agents, have demonstrated a significant reduction in CRP [17, 20]. Only two studies evaluating patients receiving DMARDs only have failed to show a
significant reduction in CRP [24, 26]. One of these studies
was in patients receiving ‘triple therapy’, an approach
considered equivalent to biologic treatment [26].
Furthermore, all RA studies of statins that have included
subjects using biologic therapy or JAK inhibition [with the
exception of one (Tang et al.)] have failed to observe a
significant reduction in CRP [19, 25, 2729]. Thus, our
study, which included subjects treated with DMARDs
and biologic therapies, is consistent with these previous
observations. It is of interest that within the small

https://academic.oup.com/rheumatology

subgroup of subjects who were not taking biologics, we
observed trends suggesting that lovastatin reduced
serum CRP, and was associated with increased percentages of subjects achieving significant reductions in CRP
from baseline (P-value = 0.007 and 0.019 for 20% and
15%, respectively). One can postulate that subjects in
this study who were receiving treatment with biologic
agents are inherently different from biologic-naı̈ve patients, and that ‘biologic treatment’ is a confounder for a
subset of patients with more severe and resistant disease
who are less likely to respond to adjunctive therapy with a
statin. Alternatively, the anti-inflammatory effect of a statin
in the context of treatment with a biologic may be minimal.
This study had several limitations. Because the study
did not fully enrol, failure to observe a difference between
arms could be a type II error. This possibility, however,
seems unlikely, as no suggestion of a trend was detected
with 55 subjects, even after performing various sensitivity
analyses. The difficulties in recruitment suggest that subjects with mild clinical disease activity and an elevated
CRP may not be representative of the majority of patients
with RA. Our observation of a potential beneficial effect of
statins in subjects not taking biologic therapy is of interest, particularly given observations of recent studies.
However, this was observed in a post hoc analysis, was
not associated with clinical benefit and must be viewed
with caution. Furthermore, the numbers of patients receiving a biologic agent targeting the same pathway (e.g. TNF)
were insufficient to develop a mechanistic hypothesis.
Factors with the potential to influence the inflammatory
response are not well defined. Concomitant therapy with a
potent biologic agent that lowers baseline CRP values
may mask or impair our ability to detect an adjunctive
benefit of statins. In contrast, patients with high disease
activity may be more susceptible to the anti-inflammatory
effects of statins. Furthermore, genetic polymorphisms
may affect CRP levels in both normal individuals and RA
patients. CRP polymorphisms may be associated with
higher (or lower) levels of CRP, but their contribution to
the responsiveness of CRP to changes in the inflammatory milieu is unclear [30]. Another possibility is that the
factors contributing to elevated acute phase reactants in
mild or moderate disease differ from those associated
with more active disease and are less responsive to intervention. In any case, the stability of autoantibody titres,
inflammatory markers, and disease activity during the trial
suggest that treatment with lovastatin was not efficacious
in the population studied.
Although we observed no anti-inflammatory or clinical
effects of lovastatin, statins may still benefit RA patients
because accelerated atherosclerosis and cardiovascular
events are increased in RA. Control of modifiable cardiovascular risk factors such as hyperlipidaemia is an important component of the care of these patients. Interestingly,
although reduced lipids (i.e. low-density lipoprotein) are
associated with an increased risk of cardiovascular disease in RA, treatment with DMARDs may result in an increase in serum lipids yet a reduction in cardiovascular
disease, the ‘lipid paradox’ (reviewed in 31). Nevertheless,
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initiation of statins in RA patients has been shown to be
associated with decreased mortality [31]. Identification of
subpopulations of RA patients who may have an antiinflammatory response to statins remains to be demonstrated in future studies [32].
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